J&J drops development of combination arthritis drug-February 2024-www.financetom.com

J&J drops development of combination arthritis drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

J&J drops development of combination arthritis drug

Aug 28, 2025 2:35 PM

Aug 28 (Reuters) - Johnson & Johnson ( JNJ ) said on

Thursday it has decided not to proceed with the development of

its combination drug in patients with a type of arthritis, after

results from a mid-stage trial did not show sufficient benefit.

Previous page： Real estate developer St Joe Q3 net income surges on higher homesite prices Next page： Medpace Holdings Insider Sold Shares Worth $9,120,486, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Real estate developer St Joe Q3 net income surges on higher homesite prices

Oct 29, 2025

Overview * St Joe Q3 net income rises 130% yr/yr to $38.7 mln * Company Q3 revenue grows 63% yr/yr to $161.1 mln * Real estate revenue jumps 199% in Q3, driven by higher homesite prices Outlook * Company did not provide specific future financial guidance in its press release Result Drivers * REAL ESTATE GROWTH - Real estate revenue...

Medpace Holdings Insider Sold Shares Worth $9,120,486, According to a Recent SEC Filing

Oct 29, 2025

05:02 PM EDT, 10/29/2025 (MT Newswires) -- Stephen P Ewald, General Counsel & Corporate Secretary, on October 27, 2025, sold 15,230 shares in Medpace Holdings ( MEDP ) for $9,120,486. Following the Form 4 filing with the SEC, Ewald has control over a total of 13,343 common shares of the company, with 13,343 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1668397/000167729725000004/xslF345X05/wk-form4_1761771495.xml ...

Canada's Aecon Group beats Q3 revenue estimates

Oct 29, 2025

Overview * Aecon Q3 2025 revenue grows 20%, beating analyst expectations * Operating profit for Q3 decreased due to negative gross profit from legacy projects * Company reports record backlog of $10,777 mln, highest in history Outlook * Aecon ( AEGXF ) expects 2025 revenue to exceed 2024, driven by a $10.8 bln backlog * Company anticipates further revenue growth...

Deathcare services provider Service Corp Q3 adjusted profit beats estimates on robust growth in cemetery segment

Oct 29, 2025

Overview * Service Corp ( SCI ) Q3 revenue grows 4.4% yr/yr, beating analyst expectations, per LSEG data * Adjusted EPS for Q3 beats consensus, growing 10% over prior year * Company raises 2025 cash flow guidance, indicating confidence in operational performance Outlook * Service Corporation ( SCI ) raises 2025 cash flow guidance to $910 mln-$950 mln * Company...